A0098 - Epidemiology of Anal Cancer in the Unites States: A Population-Based Study

Sunday, October 23, 2022

5:00 PM – 7:00 PM ET

Location: Crown Ballroom

Presenting Author(s)

Khaled Alsabbagh Alchirazi, MD

Cleveland Clinic
Cleveland, OH

Khaled Alsabbagh Alchirazi, MD¹, Almaza A. Albakri, MD², Motasem Alkhayyat, MD³, Ashraf Almomani, MD³, Alberto Rubio Tapia, MD¹
¹Cleveland Clinic, Cleveland, OH; ²Royal Jordanian Medical Services, Amman, Al Karak, Jordan; ³Cleveland Clinic Foundation, Cleveland, OH

Introduction: Anal cancer (AC) represents 2.7% of all gastrointestinal tract malignancies according to the American Cancer Society. Most AC are squamous cell cancer that arise from the transitional or squamous mucosa lining of the anal canal. The data in the literature regarding the epidemiology of AC are limited, therefore we aim to describe the epidemiology of AC using a large US population database.

Methods: A multi-institutional database (Explorys Inc., Cleveland, OH, USA) was surveyed. A cohort of patients with a primary malignant neoplasm of anal cancer between 1999–2022 was identified. The prevalence rate was calculated and age-, race-, and sex-based distributions were described.

Results: Of the 70,330,250 individuals in the database, 10,800 individuals with AC were identified with a prevalence rate of 15.4 per 100,000. Patients with AC were also more likely to be elderly, Caucasian, females, smokers, have a history of alcohol abuse, obesity, and diabetes. They were also more likely to have HIV and family history of malignant neoplasm of gastrointestinal tract.

Discussion: This is one of the largest US population studies to date evaluating the epidemiology of AC. The prevalence rate of AC was 15.4 per 100,000. Patients with AC were more likely to be elderly, Caucasian, females, obese, diabetic, and have HIV.

	Anal Cancer n=10,800 (%)	No Anal Cancer n=70,330,250 (%)	OR (CI)	p-value
Age
Age >65	6,810 (63%)	21,231,370 (30%)	3.95 (3.79-4.10)	< 0.0001
Sex
Female	6,160 (57%)	38,434,840 (55%)	1.10 (1.06-1.15)	< 0.0001
Risk Factors
HIV	580 (5%)	180,490 (0.3%)	22.06 (20.28-23.99)	< 0.0001
T2DM	2,550 (24%)	5,644,550 (8%)	3.54 (3.39-3.70)	< 0.0001
Obesity	2,030 (19%)	5,434,470 (8%)	2.76 (2.63-2.90)	< 0.0001
Tobacco	2,600 (24%)	6,485,500 (9%)	3.12 (2.99-3.26)	< 0.0001
Alcohol abuse	460 (4%)	1,089,430 (2%)	2.83 (2.58-3.10)	< 0.0001
Family hx of malignant neoplasm of GI tract	770 (7%)	594,590 (1%)	9.00 (8.37-9.69)	< 0.0001

Table: Table 1. Baseline characteristics of Anal cancer patients. Univariate analysis used to calculate OR. OR; odds ratio, CI; confidence interval, T2DM; type 2 diabetes mellitus, HIV; human immunodeficiency virus. GI; gastrointestinal.

Disclosures:

Khaled Alsabbagh Alchirazi indicated no relevant financial relationships.

Almaza Albakri indicated no relevant financial relationships.

Motasem Alkhayyat indicated no relevant financial relationships.

Ashraf Almomani indicated no relevant financial relationships.

Alberto Rubio Tapia indicated no relevant financial relationships.

Khaled Alsabbagh Alchirazi, MD¹, Almaza A. Albakri, MD², Motasem Alkhayyat, MD³, Ashraf Almomani, MD³, Alberto Rubio Tapia, MD¹. A0098 - Epidemiology of Anal Cancer in the Unites States: A Population-Based Study, ACG 2022 Annual Scientific Meeting Abstracts. Charlotte, NC: American College of Gastroenterology.